Alibaba Cloud's 45% Growth Steals the Spotlight: BABA's Most Important New Story Begins to Materialize

Опубліковано о 2026-08-21Востаннє оновлено о 2026-08-21

Анотація

For BABA, the key going forward is not just about launching more powerful models, but also converting model usage into cloud revenue, and ultimately ensuring that revenue growth outpaces cost growth. Twelve consecutive quarters of high AI product growth and this quarter’s 45% cloud growth at least prove that the first step has already happened. Short-term profit pressure should not be overlooked, but Alibaba is rewriting the market’s valuation approach with an AI business that can be verified by financial figures.

Summary

Alibaba's AI and cloud computing services revenue grew 45% year-over-year to 48.4 billion yuan, with AI product revenue maintaining triple-digit growth for the 12th consecutive quarter. Although capital expenditures of 67.68 billion yuan and negative free cash flow depressed short-term profitability, the simultaneous acceleration in customer demand, product revenue, and cloud business scale indicates that Alibaba's AI investments are no longer just expenses but are also starting to generate visible revenue.

If only looking at the approximately 75% drop in net profit, Alibaba's quarterly results would be hard to get excited about. But shifting the focus to the cloud business paints a completely different picture: AI and cloud computing services revenue grew 45% year-over-year to 48.44 billion yuan, becoming the most eye-catching number in the entire earnings report.

The significance of this growth rate is not just "more cloud sales." Alibaba relied on Taobao, Tmall, and other e-commerce businesses for traffic and cash flow for a long time. Now, AI cloud is taking on a new growth mission. It addresses the real needs of enterprises for training models, deploying intelligent agents, calling inference services, and expanding computing power. Its revenue sources are also closer to the growth logic of global tech companies like Microsoft Azure and Google Cloud.

AI Revenue Has Sustained Rapid Growth for 12 Consecutive Quarters

This quarter, Alibaba's AI-related product revenue reached 12.38 billion yuan, marking the 12th consecutive quarter of triple-digit year-over-year growth. Continuity is more important than a single-quarter surge: it indicates that customer AI usage is not a one-time experiment but is gradually transforming into stable computing and model inference demand.

Alibaba is also expanding its product coverage. The Qwen series includes both enterprise-focused model and agent capabilities, as well as lightweight versions that can run on consumer-grade hardware. For enterprise clients, Alibaba can provide a complete solution from chips, computing power, and models to application deployment; for developers, its open-source and open-weight strategy lowers the barrier to experimentation. The more users there are, the easier it is for cloud training, inference, and storage demands to solidify into revenue.

Currently, the Biggest Controversy is the Speed of Investment

Growth does not come without cost. Alibaba's capital expenditures this quarter increased 75% year-over-year to approximately 67.68 billion yuan, with free cash flow showing a net outflow of 44.67 billion yuan. The market initially expressed concern with a drop of nearly 5% at the open: even with strong AI prospects, investing too fast can depress current profits and increase the risk of returns falling short of expectations.

On the other hand, AI infrastructure exhibits clear economies of scale. Once data centers and computing platforms are built, they can serve more enterprises and developers simultaneously. As long as cloud revenue continues its high growth rate, early-stage investments have the opportunity to be diluted by a larger customer base. Citi also noted that with Alibaba's increased disclosure, investors can more clearly see the relationship between AI investments and business progress.

For BABA, the key going forward is not just to continue releasing more powerful models, but to convert model usage into cloud revenue, and to ensure that revenue growth ultimately outpaces cost growth. The 12 consecutive quarters of high AI product growth and this quarter's 45% cloud growth rate at least prove that the first step is already happening. The pressure on short-term profits cannot be ignored, but Alibaba is rewriting the market's valuation approach with an AI business that can be verified by financial numbers.

Пов'язані матеріали

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit25 хв тому

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit25 хв тому

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit25 хв тому

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit25 хв тому

Торгівля

Спот
活动图片